UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia

Frontiers in oncology, 2021-03, Vol.11, p.631570-631570

2021

Link zum Volltext

Verfügbarkeit prüfen

Rapid and sustained molecular response to nilotinib in a patient with sub-optimal response to imatinib

Clinical management issues, 2015-10, Vol.5 (3S), p.25-28

Annunziata, Mario

2015

Link zum Volltext

Verfügbarkeit prüfen

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach

Clinical management issues, 2015-10, Vol.6 (2S), p.3-5

Annunziata, Mario

2015

Link zum Volltext

Verfügbarkeit prüfen

Nilotinib therapy in an imatinib intolerant chronic myeloid leukemia patient with pulmonary severe hypertension

Clinical management issues, 2015-10, Vol.4 (2S), p.17-20

Annunziata, Mario

2015

Link zum Volltext

Verfügbarkeit prüfen

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia

Frontiers in oncology, 2020-06, Vol.10, p.883-883

2020

Link zum Volltext

Verfügbarkeit prüfen

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Frontiers in oncology, 2022-01, Vol.11, p.804714-804714

2022

Link zum Volltext

Verfügbarkeit prüfen

Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs

American journal of hematology, 2020-10, Vol.95 (10), p.E260-E263

2020

Link zum Volltext

Verfügbarkeit prüfen

The multi‐tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real‐world data

European journal of haematology, 2020-07, Vol.105 (1), p.3-15

2020

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Genetic Analysis of PEG-Asparaginase Induced Severe Hypertriglyceridemia in an Adult With Acute Lymphoblastic Leukaemia

Frontiers in genetics, 2022-02, Vol.13, p.832890

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib

Frontiers in oncology, 2021-05, Vol.11, p.672287-672287

2021

Link zum Volltext

Verfügbarkeit prüfen

Hardening transition in a one-dimensional model for ferrogels

The Journal of chemical physics, 2013-05, Vol.138 (20), p.204906-204906

2013

Link zum Volltext

Verfügbarkeit prüfen

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26 + leukemia stem cells

Frontiers in pharmacology, 2023, Vol.14, p.1194712-1194712

2023

Link zum Volltext

Verfügbarkeit prüfen

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Leukemia research, 2015-10, Vol.39 (10), p.1055-1059

2015

Link zum Volltext

Verfügbarkeit prüfen

Haematological Drugs Affecting Lipid Metabolism and Vascular Health

Biomedicines, 2022-08, Vol.10 (8), p.1935

2022

Link zum Volltext

Verfügbarkeit prüfen

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Cancer medicine (Malden, MA), 2019-06, Vol.8 (6), p.2802-2809

2019

Link zum Volltext

Verfügbarkeit prüfen

CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1295-1300

2000

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 363

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(330)
Mit Volltextzugriff
(332)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(226)
Life Sciences & Biomedicine
(200)
Humans
(148)
Female
(98)
Male
(89)
Middle Aged
(74)
Aged
(72)
Adult
(64)
Hematology
(64)
Oncology
(49)
Treatment Outcome
(36)
Biological And Medical Sciences
(34)
Chronic Myeloid Leukemia
(31)
Medical Sciences
(30)
Patients
(30)
Aged, 80 And Over
(28)
Retrospective Studies
(27)
Physical Sciences
(26)
Biochemistry & Molecular Biology
(25)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia

Rapid and sustained molecular response to nilotinib in a patient with sub-optimal response to imatinib

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach

Nilotinib therapy in an imatinib intolerant chronic myeloid leukemia patient with pulmonary severe hypertension

Residual Peripheral Blood CD26 + Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs

The multi‐tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real‐world data

Case Report: Genetic Analysis of PEG-Asparaginase Induced Severe Hypertriglyceridemia in an Adult With Acute Lymphoblastic Leukaemia

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib

Hardening transition in a one-dimensional model for ferrogels

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26 + leukemia stem cells

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study

Haematological Drugs Affecting Lipid Metabolism and Vascular Health

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy

Suchergebnisse filtern